Literature DB >> 177701

Mouse or man? Which are pertussis vaccines to protect?

N W Preston, T N Stanbridge.   

Abstract

Type 1 strains of Bordetella pertussis can infect mouse brain and have been recovered as type 1 organisms after death. When introduced into the naso-pharynx of the marmoset, they immediately acquired agglutinogen 2 or 3, and the resulting type 1,2 or 1,3 infection persisted for many weeks. As in the child, agglutinogens 2 and/or 3 appear to be essential for infection of the marmoset, whereas they are quite unnecessary in mouse brain. A vaccine (extract or whole cell) containing agglutinogen 1 may be sufficient to pass the mouse protection test but it may fail to immunize children. The mouse test is inadequate even for the screening of such extracts.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 177701      PMCID: PMC2129630          DOI: 10.1017/s0022172400055145

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  19 in total

1.  Type-specific immunity against intracerebral pertussis infection in mice.

Authors:  N W PRESTON; P EVANS
Journal:  Nature       Date:  1963-02-02       Impact factor: 49.962

2.  The relation between agglutinin production by pertussis vaccines and their immunising potency in mice.

Authors:  N W PRESTON; W A TE PUNGA
Journal:  J Pathol Bacteriol       Date:  1959-07

3.  The use of spheroplast-derived strains to differentiate between Bordetella pertussis heat-labile agglutinogens and protective antigen for mice.

Authors:  J M Dolby; C J Bronne-Shanbury
Journal:  J Biol Stand       Date:  1975

4.  Mouse Protection Tests in the Study of Pertussis Vaccine: A Comparative Series Using the Intracerebral Route for Challenge.

Authors:  P L Kendrick; G Eldering; M K Dixon; J Misner
Journal:  Am J Public Health Nations Health       Date:  1947-07

5.  Antigenic structure and phase variation in Bordetella pertussis.

Authors:  Y Nakase; K Takatsu; T Kasuga
Journal:  Jpn J Microbiol       Date:  1969-09

6.  Variation in Bordetella pertussis.

Authors:  J Cameron
Journal:  J Pathol Bacteriol       Date:  1967-10

7.  What makes a good pertussis vaccine?

Authors:  N W Preston
Journal:  Prog Drug Res       Date:  1975

8.  Vaccine composition in relation to antigenic variation of the microbe: is pertussis unique?

Authors:  N W Preston
Journal:  Prog Drug Res       Date:  1975

9.  Bordetella pertussis culture having only species factor 1.

Authors:  G Eldering; J Holwerda; J Baker
Journal:  J Bacteriol       Date:  1966-05       Impact factor: 3.490

10.  Antigens of Bordetella pertussis V. Separation of Agglutinogen 1 and Mouse-Protective Antigen.

Authors:  R F Ross; J Munoz
Journal:  Infect Immun       Date:  1971-02       Impact factor: 3.441

View more
  6 in total

1.  Prevalent serotypes of Bordetella pertussis in non-vaccinated communities.

Authors:  N W Preston
Journal:  J Hyg (Lond)       Date:  1976-08

2.  Immunogenicity of specific Bordetella pertussis surface antigens in diphtheria-tetanus-pertussis (DTP) vaccines.

Authors:  A C Blaskett; J C Cox
Journal:  Epidemiol Infect       Date:  1988-06       Impact factor: 2.451

3.  Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis.

Authors:  Y Sato; K Izumiya; H Sato; J L Cowell; C R Manclark
Journal:  Infect Immun       Date:  1981-03       Impact factor: 3.441

4.  Synergistic effect of Bordetella pertussis lymphocytosis-promoting factor on protective activities of isolated Bordetella antigens in mice.

Authors:  A Robinson; L I Irons
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

5.  Aerosol infection of mice with Bordetella pertussis.

Authors:  Y Sato; K Izumiya; H Sato; J L Cowell; C R Manclark
Journal:  Infect Immun       Date:  1980-07       Impact factor: 3.441

6.  Mouse-protecting and histamine-sensitizing activities of pertussigen and fimbrial hemagglutinin from Bordetella pertussis.

Authors:  J J Munoz; H Arai; R L Cole
Journal:  Infect Immun       Date:  1981-04       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.